Summary
L-Dopa supplemented by a peripheral decarboxylase inhibitor is considered the most potent therapeutic regimen prolonging active life in Parkinsonian patients. The long-term benefit of therapy is limited by adverse effects, such as dyskinesia and on-off phenomena, which can be mitigated by the concomitant administration of dopamine agonists, such as bromocriptine. In order to quantify the beneficial impact of early combination therapy, a controlled clinical trial (PRADO:PRA vi-del1 +DOpa) in patients with early Parkinson's disease was carried out, whereby L-Dopa monotherapy (in a fixed combination with benserazide (DoBe) was being compared with the same combination plus bromocriptine (DoBeBro). Patients were recruited and treated by 101 practising neurologists in the Federal Republic of Germany and in Hungary. 'Twenty seven clinical university centers cross-checked the patients at regular intervals. The trial started with 3 months of DoBe monotherapy (median dose of 375 mg L-Dopa for both randomized groups) followed by gradual substitution of DoBe by bromocriptine over 3 months in one of the groups (250 mg L-Dopa/10 mg bromocriptine). The target medication was maintained from study months 6 to 54.
Parkinsonian symptoms were classified according to the Webster rating scale, the Hoehn and Yahr scale and the Zung Self-Rating Depression Scale. Adverse events and life status were checked at regular intervals. Special emphasis was given to motor performance tests. 587 patients (302 in the DoBe group and 285 in the DoBeBro group) were available for intention-to-treat analysis. Both groups were homogeneous at baseline in all observed parameters. DoBe and DoBeBro proved equi-effective in terms of antiparkinsonian activity after the substitution phase (P II) had been completed. In September 1991, after a median observation period on target medication of 38.4 months in the DoBe group and 40.1 months in the DoBeBro group, 18 versus 8 deaths had been registered. The Logrank test as well as analysis using the Cox model, both adjusted for age and sex, showedP-values of 0.018 and 0.021, respectively. The mortality risk associated with L-Dopa therapy was reduced by more than 50 % by its combination with bromocriptine. The study was terminated due to this difference in mortality. The causes of death were classified by the treating physicians and consultants. At the time of study termination 152 patients in the DoBe group and 121 in the DoBeBro group had already discontinued study medication. Of those further 26 patients had died by the date of the final evaluation, 15 on DoBe and 11 on DoBeBro.
The results imply that combination therapy with bromocriptine should be preferred over L-Dopa monotherapy from the very beginning.
Similar content being viewed by others
References
Hoehn HM (1983) Parkinsonism treated with levodopa, progression and mortality. J Neurol Transm 19 [Suppl]: 253–264
Guillard A, Chastany C, Fenelon G (1986) Etude à long terme de 416 cas de maladie de parkinson. Facteurs de pronostic et implications thérapeutiques. Rev Neurol (Paris) 142: 207–214
Muenter MD, Tyce GM (1971) L-Dopa therapy of parkinson disease plasma L-Dopa concentration therapeutic response and side effects. Mayo Clin Pro 46: 231–239
Fischer PA, Schneider E, Jacobi P et al. (1973) Langzeitstudie zur Effektivität der L-Dopa-Therapie bei Parkinson-Kranken. Nervenarzt 44: 128–135
Baas H, Fischer PA (1986) Fluktuationen der Beweglichkeit beim Parkinson-Syndrom. In: Fischer PA (ed) Spätsyndrome der Parkinson-Krankheit. Roche, Basel, pp 213–234
Cohen G (1984) Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 5: 77–82
Dexter DT, Carter C, Agid F et al. (1986) Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet II, 639–640
Sofic E, Moll G, Riederer P, Jellinger K, Gabriel E (1988) Monoaminerge Läsion bei seniler Demenz vom Alzheimer Typ (SDAT): Vorläufige Befunde. In: Beckmann H, Laux G (eds) Biologische Psychiatrie, Synopsis. Springer, Heidelberg, pp 151–157
Youdim MBH, Ben-Shachar D, Riederer P (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand 126: 47–54
Olanow CW (1990) Oxidation reactions in Parkinson's disease. Neurology 40 [Suppl 3] 32–37
Fischer PA, Przuntek H, Majer M, Welzel D (1984) Kombinationsbehandlung früher Stadien des Parkinson-Syndroms mit Bromocriptin und Levodopa. Ergebnisse einer multizentrischen Studie. Dtsch Med Wschr 109: 1279–1283
Rinne UK (1985) Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 35: 1196–1198
Calne DB, Plotkin C, Williams AC et al. (1978) Long-term treatment of parkinsonism with bromocriptine. Lancet 1: 735–737
Le Witt PA, Calne DB (1981) Recent advances in the treatment of Parkinson's disease: the role of bromocriptine. J Neural Transm 51: 175
Schneider E, Fischer PA (1982) Bromocriptin in der Behandlung der fortgeschrittenen Stadien des Parkinson-Syndroms. Dtsch Med Wschr 107: 175
Przuntek H. Welzel D, Schwarzmann D, Letzel H, Kraus PH (1992) Primary combination therapy of early Parkinson's disease. Eur Neurol (in press)
Webster DD (1968) Critical analysis of the disability in Parkinson's disease. Modern Treatment 5: 257–282
Hoehn HM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442
Zung WW (1965) A self-rating depression scale. Arch Gen Psychiat 12: 63–70
Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170
Cox DR (1972) Regression models and life tables. J R Statist Soc 34 [Ser B]: 187–220
Krutze JF, Murphy FM (1990) The changing patterns of death rates in parkinsonism. Neurology 40: 42–49
Rinne UK (1986) Dopamine agonists as primary treatment in Parkinsons's disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 519–523
Rinne UK (1987) Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 37: 826–828
Cedarbaum JM, Schleifer LS (1990) Drugs for Parkinson's disease, spasticity, and acute muscle spasms. In: Goodman S, Gilman A (eds) The pharmacological basis of therapeutics, Pergamon Press, Oxford New York, pp 463–484
Mars H (1973) Modification of levodopa effect by systemic decarboxylase inhibition. Arch Neurol 28: 91–95
Miller EM, Wiener L (1974) Ro 4-4602 and levodopa in the treatment of parkinsonism. Neurology 24: 482–486
Papavasiliou PS, Cotzias GC, Dtiby SE, Steck AJ, Fehling C, Bell MA (1972) Levodopa in parkinsonism: potentiation of central effects with a peripheral inhibitor. New Engl J Med 285: 8–14
Katz RL, Lord CO, Eakine KE (1967) Anesthetic-dopamine cardiac arrhythmias and their prevention by beta-adrenergic blockade. J Pharmacol Exp Ther 158: 40–45
Boomsma F, Meerwaldt JD, Man in't Veld AJ, Hovestadt A, Schalekamp MADH (1989) Treatment of idiopathic parkinsonism with L-Dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-Dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. J Neurol 236: 223–230
Hof RP, Hof A (1981) Acceleration of blood in the aorta: a parameter useful for evaluating cardiotonic and afterload reducing substances. J Pharmacol Methods 6: 87–95
Sowers JR (1981) Dopaminergic control of circadian norepinephrine levels in patients with essential hypertension. J Clin Endocrinol Metab 53: 1133–1137
Nilsson A, Hoekfelt B (1977) Effect of bromocriptine on blood pressure, plasma and urinary catecholamines and plasma renin activity (pra) in patients with agromegaly. Acto Endocr 85 [Suppl 212] 95
Van Loon GR, Sole MJ, Bain J, Ruse JL (1979) Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 28: 425–434
Starke K, Majewski J, Ensinger H et al. (1986) In vivo operation of prejunctional adrenoceptors in the peripheral sympathetic nervous system. In: Grobecker H, Philippu A, Starke K (eds) New aspects of the role of adrenoceptors in the cardiovascular system. Springer, Berlin Heidelberg New York, p 43
Falk RH, Desilva RD, Lown B (1981) Reduction in vulnerability to ventricular fibrillation by bromocriptine, a dopamine agonist. Cardiovasc Res 15: 175–180
Meredith IT, Broughton A, Jennings GL, Esler MD (1991) Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. New Engl J Med 325: 618–624
Author information
Authors and Affiliations
Additional information
Dedicated to E. D. Schneider on the occasion of this 60th birthday.
Pravidel = brand of Bromocriptine
Rights and permissions
About this article
Cite this article
Przuntek, H., Welzel, D., Blümner, E. et al. Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado-study discontinued. Eur J Clin Pharmacol 43, 357–363 (1992). https://doi.org/10.1007/BF02220609
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02220609